An assessment of the global usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy.
Generic PROMs are more likely to be usable and accessible for assessing quality of life in children receiving rhGH therapy, while cost and unclear fee structures pose significant barriers for condition-specific measures.
Where it sits
this study against the rest of the hgh (somatropin) corpusSummary and findings
This study evaluated the usability of quality-of-life questionnaires in children receiving recombinant growth hormone therapy. A total of 50 patient-reported outcome measures (PROMs) were identified, with 37 remaining after exclusions. Key findings included that 16 (43%) were available in self-report and parent-proxy formats in over 30 languages.
Abstract
<h4>Background</h4>In the field of childhood growth hormone therapy (rhGH), patient and parent/observer-reported outcome measures (PROMs) are rarely used routinely.<h4>Aim</h4>To identify barriers and facilitators for the global implementation of PROMs for evaluating QoL in children receiving rhGH.<h4>Methods</h4>PROMs used in childhood rhGH therapy that were identified through a narrative literature search and expert group consultation were evaluated on reporter's perspective, language availability, administration mode, cost, age range, and completion time.<h4>Results</h4>Of the 50 PROMs identified, 13 were excluded due to methodological limitations. Of the remaining 37, that included 26 generic and 11 condition-specific PROMs, 16 (43%) were available in self-report and parent-proxy formats in over 30 languages and 24 (65%) had a reported completion time less than 15 min. The median lower age limit was 7 yrs (range: 3.0, 12.7). Of the 37, 7 (19%) were free to use, 12 (32%) required a fee, and for 18 (49%), the cost was unclear or varied between clinical practice and research. The mostly commonly represented domains in the condition-specific PROMs included "physical functioning & symptoms" and "emotional & mental health". Fees for condition-specific PROMs were often not explicit, and none were unconditionally free of charge. Overall, generic PROMS tended to rank higher across the six usability parameters than condition-specific tools.<h4>Conclusion</h4>Cost and unclear fee structures represent barriers to the routine use of condition-specific PROMs for assessing rhGH therapy in real-world settings. Whilst both, generic and condition-specific PROMs play important complementary roles, the former are more likely to exhibit characteristics that support global implementation.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.